Search arXiv⌕ Search
Home/Archive/arXiv

arXiv · 1805.01789

The conformable fractional grey system model

Xin Ma·Wenqing Wu·Bo Zeng·Yong Wang·Xinxing Wu
View original source ↗Read source document ↗Export metadata ↓

Abstract

The fractional order grey models (FGM) have appealed considerable interest of research in recent years due to its higher effectiveness and flexibility than the conventional grey models and other prediction models. However, the definitions of the fractional order accumulation (FOA) and difference (FOD) is computationally complex, which leads to difficulties for the theoretical analysis and applications. In this paper, the new definition of the FOA are proposed based on the definitions of Conformable Fractional Derivative, which is called the Conformable Fractional Accumulation (CFA), along with its inverse operation, the Conformable Fractional Difference (CFD). Then the new Conformable Fractional Grey Model (CFGM) based on CFA and CFD is introduced with detailed modelling procedures. The feasibility and simplicity and the CFGM are shown in the numerical example. And the at last the comprehensive real-world case studies of natural gas production forecasting in 11 countries are presented, and results show that the CFGM is much more effective than the existing FGM model in the 165 subcases.

Explore related subjects

stat.ME

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Xin Ma, Wenqing Wu, Bo Zeng, Yong Wang, Xinxing Wu. 2019-07-05. The conformable fractional grey system model. https://doi.org/10.1016/j.isatra.2019.07.009

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

Considerations for the Integration of Randomized Controlled Trials and Real-World Data

As clinical decision-making increasingly moves toward individualized and context-specific treatment recommendations, reliance on any single evidence source, randomized or observational, may be insufficient. Principled integration of randomized controlled trials and real-world data, grounded in explicit causal frameworks, offers a path toward evidence that is both internally credible and externally relevant. In this article, we describe distinct objectives for the integration of randomized controlled trials and real-world data and discuss how these objectives shape key design and analytic considerations, illustrating the resulting choices through example estimands. We highlight practical issues that commonly arise in applied settings, including data relevance and curation, cross-source comparability, estimand specification, and sensitivity analysis. We aim for this article to help readers evaluate and implement principled approaches to integrating randomized controlled trials and real-world data in ways that can support more reliable treatment recommendations while maintaining regulatory-grade evidentiary standards.

stat.ME↗
arXiv2026

Validity of MMRM-based hypothesis testing under missing-not-at-random mechanisms

In randomized clinical trials with longitudinal continuous outcomes, missing-not-at-random (MNAR) missingness often motivates conservative alternatives to mixed models for repeated measures (MMRM). Such caution is important for estimation, but estimation and testing need not require identical assumptions. Moreover, overly conservative primary analyses may reduce power, increase required sample size, and raise trial costs. We investigated the validity of MMRM-based testing under the global null of identical longitudinal outcome distributions across groups. Because valid testing minimally requires treatment-effect estimators to converge to the null under the null hypothesis, we investigated sufficient conditions for this property. We introduced a proportional observation condition requiring ratios of observation probabilities relative to a reference group, conditional on the full outcome vector, to be outcome-independent, and showed that, with arbitrary post-baseline visits and monotone missingness, this condition is sufficient for convergence to the null value. The condition allows observation to depend on unobserved outcomes and permits between-group differences in overall observation probabilities through outcome-independent dropout, making it clinically interpretable while accommodating outcome-dependent MNAR missingness. Synthetic and data-based bootstrap simulations showed negligible bias and empirical test sizes near 0.05, including nonmonotone missingness. Thus, MNAR missingness does not by itself imply that a more conservative primary testing procedure is required. This result does not justify treatment-effect estimation under alternatives, which still requires estimand-based interpretation and sensitivity analyses.

stat.ME↗
arXiv2026

Optimized variance estimation under interference and complex experimental designs

Unbiased and consistent variance estimators generally do not exist for design-based treatment effect estimators because experimenters never observe more than one potential outcome for any unit. The problem is exacerbated by interference and complex experimental designs. Experimenters must accept conservative variance estimators in these settings, but they can strive to minimize the conservativeness. In this paper, we show that the task of constructing a minimally conservative variance estimator can be interpreted as an optimization problem that aims to find the lowest estimable upper bound of the true variance given the experimenter's risk preferences and knowledge of the potential outcomes. We characterize the set of admissible bounds in the class of quadratic forms, and we demonstrate that the optimization problem is a convex program for many natural objectives. The resulting variance estimators are guaranteed to be conservative regardless of whether the background knowledge used to construct the bound is correct, but the estimators are less conservative if the provided information is reasonably accurate. Numerical results show that the resulting variance estimators can be considerably less conservative than existing estimators, allowing experimenters to draw more informative inferences about treatment effects.

stat.ME↗